reference/35587858

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35587858

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
issn	2041-1723
issueIdentifier	1
pageRange	3468-
publicationName	Nature Communications
startingPage	3468
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f
bibliographicCitation	Zhao S, Zhuang W, Han B, Song Z, Guo W, Luo F, Wu L, Hu Y, Wang H, Dong X, Jiang D, Wang M, Miao L, Wang Q, Zhang J, Fu Z, Huang Y, Xu C, Hu L, Li L, Hu R, Yang Y, Li M, Yang X, Zhang L, Huang Y, Fang W. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat Commun. 2023 Jun 12;14(1):3468. PMID: 37308490; PMCID: PMC10261012.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_771f451db684e26d857cb5a194b01251 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc6d9f74fece96f2f618f1fae29521c4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a78cdda5cfadf4c086832e76cb93adbe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ad781f9cd0531a36d0806ecb45b59ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49a0ef312a64a9b02c0696ce2fc04b1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76c5bb515c2faa08330264cd1a1de15c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7dcae5dda80e6ff556bf5e5cfd91e79e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54f02c603b8d398036743420a34e8ee5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb4c710c49714d9553ead436def0df56 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b9f8cfde81788df9e446c61129c12d6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53cd8ce6f27a80af59906b1940075821 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_34eb743463b2ad7f172a63eb12dd6734 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_94ea2a52f236f9b97e448828aa0891d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89f7fdc81c6deee6d2c623b558012c59 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69330bddc880973b1409249c6911b122 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b986570f08553152d1ace0905c75a52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe3d1caa2edacc9e9e5a08b1b165eb4b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89def465702b2a6fe57e40e247b1736e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc010e156a13806ae00368df24a7bacc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d0bc0e0057713c9d907822a30b861e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1923-6975 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e50534be9c56872943f35c5e39bd072 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_62db8d75a40c60f4e985d0af85789d40 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9afbdb2c83b48240aea52fcc5361c2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ab82dc243dbc44c1707aab2cbc43e3d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_683c76a3008e72a19bf4cba043130800
date	2023-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC10261012 https://pubmed.ncbi.nlm.nih.gov/37308490 https://doi.org/10.1038/s41467-023-39139-4
isPartOf	https://portal.issn.org/resource/ISSN/2041-1723 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37539
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
discusses	http://id.nlm.nih.gov/mesh/M000603988 http://id.nlm.nih.gov/mesh/M0001357
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008175 http://id.nlm.nih.gov/mesh/D002289
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005091 http://id.nlm.nih.gov/mesh/D000911 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71496458 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453

Total number of triples: 58.